Allogene Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Allogene Therapeutics, Inc. filed a Form 8-K reporting results from its 2019 Annual Meeting of Stockholders held on June 6, 2019. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol ALLO. As of the April 22, 2019 record date, 121,530,320 common shares were outstanding and entitled to vote.
Meeting Results and Key Corporate Actions
- Director elections: Stockholders elected Arie Belldegrun, M.D., FACS; David Chang, M.D., Ph.D.; and David Bonderman as Class I directors, each to serve until the 2022 Annual Meeting and until a successor is elected and qualified.
- Accounting firm ratification: Stockholders ratified the Audit Committee’s selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Arie Belldegrun, M.D., FACS | 86,654,009 | 2,093,052 | 5,048,304 |
| David Chang, M.D., Ph.D. | 87,027,803 | 1,719,258 | 5,048,304 |
| David Bonderman | 86,306,024 | 2,441,037 | 5,048,304 |
| Accounting Firm Ratification | Votes |
|---|---|
| For | 93,645,317 |
| Against | 16,095 |
| Abstentions | 133,953 |
| Broker Non-Votes | 0 |
Financial Metrics, Liquidity, and Outlook
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or operating outlook information. It also does not disclose material changes versus a prior comparable period.
Risks, Contingencies, and Unusual Items
The filing reports only the annual meeting voting results and does not identify new risks, contingencies, unusual items, or management commentary.
Investor Verification Items
- Verify the final director election vote totals and three-year terms.
- Confirm Ernst & Young LLP’s ratification as the independent auditor for fiscal 2019.
- Review the company’s quarterly and annual SEC filings for financial performance, cash runway, debt, clinical-program developments, and risk disclosures, none of which are addressed in this 8-K.